Get it on Google Play

Oblenio Bio doses first patients in Phase 1a trial of LBL-051

August 4, 2026 7:56 AM EDT Send to a Friend
Nanjing Leads Biolabs Co., Ltd. (9887.HK) announced that Oblenio Bio, its partner company formed with Aditum Bio, has dosed the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login